The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice

Statins and Their Effect on PCSK9—Impact and Clinical Relevance

(2016) Beth A. Taylor et al.   Current Atherosclerosis Reports

Vaccine strategies for lowering LDL by immunization against proprotein convertase subtilisin/kexin type 9

(2016) Bryce Chackerian et al.   CURRENT OPINION IN LIPIDOLOGY

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

(2016) Alberico L. Catapano et al.   EUROPEAN HEART JOURNAL

A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality

(2016) Rishi K. Wadhera et al.   Journal of Clinical Lipidology

2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

(2016) Donald M. Lloyd-Jones et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Local effects of human PCSK9 on the atherosclerotic lesion

(2015) Ilaria Giunzioni et al.   JOURNAL OF PATHOLOGY

Effect of Naturally Random Allocation to Lower Low-Density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms in NPC1L1, HMGCR, or Both

(2015) Brian A. Ference et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

(2015) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

A cholesterol-lowering VLP vaccine that targets PCSK9

(2015) Erin Crossey et al.   VACCINE

PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE

(2014) Brandon Ason et al.   JOURNAL OF LIPID RESEARCH

Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin

(2014) Susan Kühnast et al.   JOURNAL OF LIPID RESEARCH

Peptide-Based Anti-PCSK9 Vaccines - An Approach for Long-Term LDLc Management

(2014) Gergana Galabova et al.   PLoS One

PCSK9 is a critical regulator of the innate immune response and septic shock outcome

(2014) K. R. Walley et al.   Science Translational Medicine

Active immunotherapy for chronic diseases

(2013) Martin F. Bachmann et al.   VACCINE

Immunization against proprotein convertase subtilisin-like/kexin type 9 lowers plasma LDL-cholesterol levels in mice

(2012) Elena Fattori et al.   JOURNAL OF LIPID RESEARCH

Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

(2011) Geertje M. Bartelds   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation

(2010) George S. Abela   Journal of Clinical Lipidology

PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain

(2010) Mali Liu et al.   JOURNAL OF LIPID RESEARCH

NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals

(2010) Peter Duewell et al.   NATURE

Lipid Treatment Assessment Project 2

(2009) David D. Waters et al.   CIRCULATION

Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice

(2007) Willeke de Haan et al.   ATHEROSCLEROSIS